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OBJECTIVES: To evaluate the prevalence of metabolic
syndrome (MetS) and its association with physical capac-
ity, disability, and self-rated health in older adults at high
risk of mobility disability, including those with and with-
out diabetes mellitus.
DESIGN: Cross-sectional analysis.
SETTING: Lifestyle Interventions and Independence for
Elders (LIFE) Study.
PARTICIPANTS: Community-dwelling sedentary adults
aged 70 to 89 at high risk of mobility disability (Short
Physical Performance Battery (SPPB) score ≤9; mean
7.4  1.6) (N = 1,535).
MEASUREMENTS: Metabolic syndrome was defined
according to the 2009 multiagency harmonized criteria;
outcomes were physical capacity (400-m walk time, grip
strength, SPPB score), disability (composite 19-item score),
and self-rated health (5-point scale ranging from excellent
to poor).
RESULTS: The prevalence of MetS was 49.8% in the
overall sample (83.2% of those with diabetes mellitus,
38.1% of those without). MetS was associated with stron-
ger grip strength (mean difference (D) = 1.2 kg, P = .01)
in the overall sample and in participants without diabetes
mellitus and with poorer self-rated health (D = 0.1 kg,
P < .001) in the overall sample only. No significant differ-
ences were found in 400-m walk time, SPPB score, or dis-
ability score between participants with and without MetS,
in the overall sample or diabetes mellitus subgroups.
CONCLUSION: Metabolic dysfunction is highly preva-
lent in older adults at risk of mobility disability, yet con-
sistent associations were not observed between MetS and
walking speed, lower extremity function, or self-reported
disability after adjusting for known and potential con-
founders. Longitudinal studies are needed to investigate
whether MetS accelerates declines in functional status in
high-risk older adults and to inform clinical and public
health interventions aimed at preventing or delaying
disability in this group. J Am Geriatr Soc 63:222–232,
2015.
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Preserving physical capacity and reducing disability areessential for maintaining independent living in older
adults. Impairments in physical capacity have been linked to
subsequent disability, hospitalization, nursing home admis-
sion, and mortality,1–5 yet they represent an early enough
stage in the disablement process to be responsive to restor-
ative interventions.6,7 Consequently, better identification of
treatable risk factors for age-related loss in physical capac-
ity, especially in older adults at high risk for disability, is
critical to efforts aimed at preventing disability.
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Metabolic syndrome (MetS), defined as a clustering of
risk factors for cardiovascular disease and type 2 diabetes
mellitus, including abdominal obesity, dyslipidemia, hyper-
tension, and impaired glucose tolerance, is increasingly
prevalent in U.S. adults aged 70 and older.8,9 Despite the
ongoing controversy over the concept of MetS and ques-
tions about whether its components are additive,10 several
existing studies suggest an association between MetS and
poorer self-reported and objectively measured functional
status in the general population of older adults.11–14 How-
ever, the link between MetS and self-reported or objec-
tively measured functional status in older adults at high
risk for disability has not been assessed. Given the high
prevalence of MetS in older adults and its potential treat-
ability,15 it is important to examine whether this clustering
of risk factors may be associated with poor physical capac-
ity and disability in individuals at high risk of disability.
In addition, numerous studies have documented the
value of self-rated health (SRH), a subjective global assess-
ment of an individual’s health status, as a predictor of
future disability and loss of independent living in older
adults.16,17 SRH has been shown to capture a wide range
of health-related phenomena, including chronic diseases,
perceived functional status, and metabolic and inflamma-
tory abnormalities,18–20 and to be a critical contributor to
overall quality of life. Yet, few published studies have
examined the association between MetS and SRH in the
general population,21 and no study (to the knowledge of
the authors of the current study) has evaluated older per-
sons at high risk of disability; such studies are needed as a
first step toward understanding whether the treatment of
MetS components might improve SRH and quality of life
in older adults.
The present study had two aims: to ascertain the
prevalence of MetS and its components in older adults at
high risk of disability in the overall sample and separately
in subgroups defined according to age, sex, race, educa-
tion, body mass index (BMI) category, and diabetes mell-
itus status and to evaluate the cross-sectional associations
between MetS and physical capacity (walking speed, grip
strength, lower extremity function), disability, and SRH
in older adults at high risk of disability. For the second
aim, it was hypothesized that participants with MetS
would score worse on all outcomes (physical capacity,
disability, SRH) than those without MetS. Describing the
demographic distribution of MetS and its components
and identifying the associations between MetS and pre-
cursors of disability in high-risk older adults may inform
clinical and public health interventions aimed at main-
taining functional status and reducing disability rates in
older adults.
METHODS
Study Design and Participants
Baseline data from the Lifestyle Interventions and Indepen-
dence for Elders (LIFE) Study, a Phase 3 multicenter ran-
domized controlled trial of 1,635 community-dwelling
sedentary older adults at high-risk of mobility disability
were used.22 The primary goal of the LIFE Study was to
compare the effects of a moderate-intensity physical activ-
ity (PA) program with those of a successful aging health
education program on the incidence of major mobility dis-
ability (inability to walk 400 m) in a vulnerable popula-
tion of older adults.
Potential participants aged 70 to 89 were deemed eli-
gible if they were sedentary (<20 min/wk of structured PA
in the past month and ≤125 min/wk of moderate PA based
on 18 items from the Community Healthy Activities
Model Program for Seniors (CHAMPS) PA question-
naire);23 at high risk of mobility disability based on objec-
tively assessed lower extremity function (Short Physical
Performance Battery (SPPB) score ≤9);24 and able to walk
400 m in less than 15 minutes unassisted without sitting
or leaning. The exclusion criteria were designed to identify
persons who were probably incapable of fully participat-
ing in the interventions because of comorbid conditions
or cognitive impairment and those for whom PA would
be unsafe. The study design, protocol, and inclusion
and exclusion criteria have been described in detail
elsewhere.22
For the present study, 100 participants for whom
MetS status could not be ascertained because of missing
data were excluded, resulting in an analytical sample of
1,535 participants.
Measures
Physical Capacity, Disability, and SRH
Three measures of physical capacity were evaluated:
400-m walk time, grip strength, and SPPB score.
Four hundred-meter walk time was the time (in sec-
onds) that each participant needed to complete a 400-m
course walking at usual speed without sitting, leaning, or
the assistance of another person or a walker. In older
adults, 400-m walk time has been associated with greater
risk of mobility limitation, disability, and mortality25 and
serves as a proxy indicator for ability to walk within the
community and thus has emerged as an important health
outcome.26
Grip strength, a commonly used measure of upper
body strength with predictive value for mortality and dis-
ability,4,27 was measured in kilograms as the average of
two maximal trials of the dominant hand (to the nearest
2 kg) with a hand dynamometer (JAMAR; Lafayette
Instrument Company, Lafayette, IN).
Short Physical Performance Battery score,24 a highly
reliable and responsive summary measure of lower
extremity function,28 comprises three hierarchical timed
tests of balance, 4-m usual pace walking, and repeated
chair stands. For each test, a five-level summary scale
from 0 (unable to perform the task) to 4 (best perfor-
mance) was created according to established procedure.24
An overall SPPB score (range 0–12) was calculated for
each participant by summing the scores on the three tests;
higher scores indicate better performance. Individuals
with SPPB scores greater than 9 were excluded from the
study.
Disability was assessed using the previously validated
Pepper Assessment Tool for Disability questionnaire.29
The items covered three domains: basic activities of daily
living (ADLs: getting in and out of a chair, getting in and
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out of a bed, gripping with hands, using the toilet, dress-
ing, getting in and out of a car, walking across a small
room, bathing), mobility (walking several blocks, lifting
heavy objects, walking one block, lifting or carrying 10
pounds, climbing several flights of stairs, climbing one
flight of stairs, walking one-quarter of a mile), and instru-
mental activities of daily living (IADLs: light housework,
participating in community activities, managing money,
visiting with relatives or friends, using the telephone, tak-
ing care of a family member). Respondents were asked to
report the level of difficulty they had with each item dur-
ing the past month; responses were coded on a 5-point
Likert scale, ranging from 1 (usually no difficulty) to 5
(unable to do), and scores were averaged to generate a
summary score, with higher mean scores denoting greater
disability.
Self-rated health was measured using participants rat-
ings of their general health status,30 as indicated by their
response to the question: “Would you say your general
health is. . .?”; ratings ranged from 1 (excellent) to 5
(poor).
Metabolic Syndrome (MetS)
MetS was defined in accordance with the harmonized cri-
teria recommended in the 2009 Joint Interim Statement
from multiple scientific associations31 as the presence of
three or more components from the following: abdominal
obesity (waist circumference ≥102 cm in men and ≥88 cm
in women measured at the midpoint between the highest
point of the iliac crest and the lowest part of the costal
margin in the midaxillary line), low high-density lipopro-
tein cholesterol HDL-C (<40 mg/dL for men and <50 mg/
dL for women or drug treatment for low HDL-C), high
triglycerides (TG) (≥150 mg/dL or drug treatment for high
TG), hypertension (systolic blood pressure ≥130 mmHg,
diastolic pressure ≥85 mmHg, or antihypertensive drug
treatment with a history of physician-diagnosed high blood
pressure), and high fasting plasma glucose (≥100 mg/dL or
drug treatment for diabetes mellitus). MetS was coded as a
binary variable (absent vs present).
Blood samples were collected after a 12-hour fast. All
samples were tested in a single laboratory; before testing,
all samples were stored and transferred according to proto-
col. Participants were asked to bring all current medica-
tions with them, and medications were reviewed at the
phlebotomy visit.
Covariates
Comorbidities
Self-reported, physician-diagnosed diabetes mellitus
(absent vs present) was recorded for stratified analyses. A
comorbidity index (range 0–5) for other conditions was
created by summing participant reports of physician-diag-
nosed angina pectoris or myocardial infarction, congestive
heart failure, stroke, and cancer (no or yes for all four
conditions) and peripheral arterial disease as determined
through measurement of ankle–brachial index (ABI).
Peripheral arterial disease was coded as absent if ABI was
0.9 or greater and present if ABI was less than 0.9.32
Cognitive status was assessed using the Modified
Mini-Mental State (3MS) examination,33 with scores rang-
ing from 0 to 100; higher scores indicate better cognitive
function.
Health Risk Factors
Body mass index was calculated from measured weight
and height (weight (kg)/height2 (m)). PA level was assessed
according to CHAMPS score (range 0–120).23 Smoking
status (nonsmoker vs current smoker) and alcohol use
(nondrinker, <1 drink/d, ≥1 drink/d) were also recorded at
baseline.
Statistical Analysis
Descriptive statistics were calculated for all variables.
Cochran-Armitage trend tests and chi-square tests were
used to compare proportions of MetS (and each compo-
nent of MetS) in baseline subgroups. Linear models were
used to compare participants with and without MetS in
unadjusted and adjusted models. The following covariates
were used in the adjusted models: demographic (sex,
race, education, age, field site), health status (comorbidity
index, 3MSE), health risk factors (BMI category,
CHAMPS score, smoking status, alcohol use), and diabe-
tes mellitus (only for the overall sample models). Differ-
ences of adjusted means and confidence intervals were
also calculated. These analyses were completed for the
overall sample and for subgroups defined on the basis of
diabetes mellitus status. No explicit adjustment was made
for multiple comparisons.
Because of earlier reports showing associations
between severity of MetS or individual MetS components
and several of the outcomes investigated here,34–37 addi-
tional analyses were performed using MetS as an ordinal
variable (to capture the severity of metabolic dysfunction
as indicated by the number of MetS components identified
in each participant) and separately with each MetS compo-
nent. All secondary analyses were adjusted for the covari-
ates described for the main analyses.
RESULTS
Participants’ demographic and health characteristics are
described in Table 1 for the full sample and separately for
participants with and without MetS; 764 (49.8%) partici-
pants had three or more MetS components, fulfilling the
requirements for MetS (MetS subgroup), and 771 (50.2%)
had two or fewer components (non-MetS subgroup). The
MetS and non-MetS subgroups were generally comparable
on all characteristics except diabetes mellitus and obesity,
both of which were substantially more common in the
MetS subgroup.
Hypertension was the most common component in
the MetS (93.2%) and non-MetS (63.8%) subgroups, fol-
lowed by abdominal obesity (92.7% and 52.8%); low
HDL-C was the least common component in both sub-
groups (42.8% and 2.2%). The majority (54.3%) of
MetS participants met three metabolic criteria, and
54.1% of non-MetS participants met two metabolic
criteria.
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Prevalence of MetS and Individual Components
Table 2 presents the prevalence of MetS and individual
MetS components according to selected participant charac-
teristics.
MetS Prevalence
The prevalence of MetS was similar in men and women
and in whites and nonwhites. Older age and greater educa-
tion were associated with progressively lower rates of
MetS. As expected, the prevalence of MetS was greater
with higher BMI category and was substantially higher in
participants with diabetes mellitus than in those without.
Individual MetS Components
Fasting glucose was the only metabolic risk factor that dif-
fered between men and women (more prevalent in men).
Racial differences were identified only in the prevalence of
high TG (higher in whites) and hypertension (higher in
nonwhites). Older age was associated with lower rates of
Table 1. Characteristics of Study Participants According to Metabolic Syndrome (MetS)
Characteristic Overall Sample, N = 1,535 With MetS, n = 764a Without MetS, n = 771
Demographic
Age, mean  SD 78.9  5.2 77.9  5.0 79.8  5.3
Female, n (%) 1,022 (66.6) 506 (66.2) 516 (66.9)
Nonwhite, n (%) 311 (20.3) 160 (21.0) 151 (19.7)
Education (years), n (%)
<High school (0–8) 41 (2.7) 26 (3.4) 15 (2.0)
High school or equivalent (9–12) 455 (29.7) 261 (34.2) 194 (25.3)
College (13–16) 607 (39.6) 290 (38) 317 (41.3)
Postgraduate or other (>16) 428 (28.0) 187 (24.5) 241 (31.4)
Health
Diabetes mellitus, n (%) 399 (26.1) 332 (43.6) 67 (8.7)
BMI, kg/m2, mean  SD 30.2  6.1 32.4  5.9 28.1  5.5
BMI, kg/m2, n (%)
<18.5 7 (0.5) 1 (0.1) 6 (0.8)
18.5–24.9 278 (18.1) 46 (6.0) 232 (30.1)
25.0–29.9 542 (35.3) 239 (31.3) 303 (39.3)
≥30.0 708 (46.1) 478 (62.6) 230 (29.8)
Number of comorbidities, mean  SD 0.6  0.8 0.6  0.8 0.5  0.7
Modified Mini-Mental State Examination score, mean  SDb 91.7  5.4 91.6  5.4 91.7  5.3
Community Healthy Activities Model Program for Seniors
physical activity score, mean  SDc
17.3  33.2 16.7  33.1 17.8  33.3
Current smoker, n (%) 46 (3.1) 16 (2.1) 30 (4.0)
Alcohol use, drinks/d, n (%)
0 932 (61.0) 509 (66.7) 423 (55.3)
<1 418 (27.4) 183 (24.0) 235 (30.7)
≥1 178 (11.6) 71 (9.3) 107 (14.0)
Metabolic syndrome criteria, n (%)
Abdominal obesityd 1,109 (72.8) 707 (92.7) 402 (52.8)
Low HDL-Ce 338 (22.2) 321 (42.8) 17 (2.2)
High triglyceridesf 448 (29.5) 400 (53.5) 48 (6.2)
Hypertensiong 1,204 (78.4) 712 (93.2) 492 (63.8)
High fasting glucoseh 775 (50.6) 634 (83.2) 141 (18.3)
Number of metabolic abnormalities, mean  SD 2.5  1.3 3.6  0.8 1.4  0.7
Number of metabolic abnormalities, n (%)
0 88 (5.7) – 88 (11.4)
1 266 (17.3) – 266 (34.5)
2 417 (27.2) – 417 (54.1)
3 415 (27.0) 415 (54.3) –
4 216 (14.1) 216 (28.3) –
5 133 (8.7) 133 (17.4) –
Missing values account for the small discrepancies between total n (in each column) and the values listed under each descriptive characteristic.
a ≥3 criteria.
b Range 0–100; higher score indicates better cognitive function.
c Range 0–120; higher score indicates higher levels of physical activity.
d Waist circumference ≥102 cm in men, ≥88 cm in women.
e <40 mg/dL for men, <50 mg/dL for women or drug treatment for low high-density lipoprotein cholesterol (HDL-C).
f ≥150 mg/dL or drug treatment for high triglycerides.
g Systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or antihypertensive drug treatment with a history of physician-diagnosed
hypertension.
h ≥100 mg/dL or drug treatment for diabetes mellitus.
SD = standard deviation; BMI = body mass index.
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all metabolic abnormalities except hypertension, and
higher education was associated with lower rates of all cri-
teria except high fasting glucose. The prevalence of each
metabolic component was greater with higher BMI and
was higher in participants with diabetes mellitus than in
those without.
Associations Between MetS and Physical Capacity,
Disability, and SRH
The results from unadjusted analyses (shown in Table 3
for the full sample and separately according to MetS sta-
tus) indicate that participants with MetS walked more
Table 2. Prevalence of Metabolic Syndrome (MetS) and Individual Components According to Selected Sample
Characteristics (N = 1,535)
Characteristic
MetS
(≥3 Criteria)
Abdominal
Obesitya
Low
HDL-Cb
High
Triglyceridesc Hypertensiond
High Fasting
Glucosee
Age
70–74 59.2 85.6 25.7 33.5 77.9 56.2
75–79 54.1 75.5 23.7 30.5 79.9 53.6
80–84 45.2 67.2 21.8 29.9 78.4 48.0
85–89 32.4 53.8 13.9 19.7 76.9 39.2
P-value <.001 <.001 .001 .001 .76 <.001
Sex
Female 49.5 74.3 22.1 29.5 79.1 47.3
Male 50.3 69.8 22.5 29.5 77.2 57.2
P-value .77 .07 .87 .97 .40 <.001
Race
Nonwhite 51.4 77.0 18.3 19.4 86.5 53.7
White 49.4 71.7 23.3 32.1 76.3 49.8
P-value .52 .06 .06 <.001 <.001 .22
Education (years)
<High school (0–8) 63.4 78.0 41.5 43.9 80.5 61.0
High school or equivalent (9–12) 57.4 76.9 24.3 30.9 84.6 53.7
College (13–16) 47.8 70.9 21.1 30.2 76.6 48.6
Postgraduate or other (>16) 43.7 70.5 20.0 25.9 74.5 49.5
P-value <.001 .02 .01 .02 <.001 .09
Body mass index, kg/m2
<18.5 14.3 0.0 14.3 14.3 85.7 28.6
18.5–24.9 16.5 14.5 13.7 17.4 64.4 29.2
25.0–29.9 44.1 69.3 20.4 27.8 78.4 47.6
≥30.0 67.5 98.7 27.1 35.7 83.9 61.4
P-value <.001 <.001 <.001 <.001 <.001 <.001
Diabetes mellitus diagnosis
No 38.1 68.8 18.2 26.4 76.2 35.2
Yes 83.2 84.1 34.1 38.8 85.0 94.5
P-value <.001 <.001 <.001 <.001 <.001 <.001
Chi-square tests were used when comparing two subgroups and the Cochran-Armitage trend tests for more than two subgroups.
a Waist circumference ≥102 cm in men, ≥88 cm in women.
b <40 mg/dL for men, <50 mg/dL for women or drug treatment for low high-density lipoprotein cholesterol (HDL-C).
c ≥150 mg/dL or drug treatment for high triglycerides.
d Systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or antihypertensive drug treatment with a history of physician-diagnosed
hypertension.
e ≥100 mg/dL or drug treatment for diabetes mellitus.
Table 3. Physical Capacity, Disability Score, and Self-Rated Health According to Metabolic Syndrome (MetS)
Overall Sample, N = 1,535 With MetS, n = 764 Without MetS, n = 771 P-Valuea
Mean  Standard Deviation
Physical Capacity
400-m walk time, seconds 508.5  113.7 518.4  115.8 498.7  110.8 .001
Grip strength, kg 23.6  9.4 24.4  9.9 22.9  8.8 .002
Short Physical Performance Battery scoreb 7.38  1.59 7.35  1.60 7.40  1.58 .48
Disability scorec 1.40  0.39 1.43  0.40 1.37  0.38 .01
Self-rated healthd 2.76  0.77 2.87  0.74 2.64  0.78 <.001
a P-values for unadjusted differences in physical capacity measures, disability score, and self-rated health between participants with and without MetS.
b Range 1 (low) to 9 (high).
c Range 1 (no difficulty reported) to 5 (unable to do tasks).
d Range 1 (excellent) to 5 (poor).
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slowly on the 400-m walk test and had higher disability
scores and worse SRH than those without MetS. Grip
strength was significantly higher in participants with MetS
than in those without. SPPB scores were similar in the two
subgroups.
The mean estimated differences in all outcome scores
from the unadjusted and adjusted models are presented in
Table 4.
In the overall sample, MetS was associated with stron-
ger grip strength, although the mean difference was dimin-
ished in the adjusted model (1.2 kg, P = .01 adjusted vs
1.6 kg, P = .001 unadjusted). After adjustment for all co-
variates (listed in the footnote to Table 4), the associations
between MetS and 400-m walking speed and between
MetS and disability score were not statistically significant.
MetS was not associated with SPPB scores in the unad-
justed or adjusted models, although in both sets of models,
SRH scores were significantly worse (higher) in individuals
with MetS.
In participants with diabetes mellitus, there was no
significant association between MetS and any of the physi-
cal capacity measures in unadjusted or adjusted analyses.
The differences in disability and SRH scores observed
between individuals with MetS and diabetes mellitus and
those with diabetes mellitus without MetS were not statis-
tically significant after adjustment for the demographic
and health covariates. In participants without diabetes
mellitus, MetS was associated with stronger grip strength
in unadjusted and adjusted models, but no association was
observed between MetS and the remaining four outcomes
in the adjusted models.
Secondary analyses (data available upon request) with
MetS as an ordinal variable showed that SRH worsened
progressively as the number of MetS components increased
(b = 0.04, P = .01), but the severity of MetS was not sig-
nificantly associated with any of the other outcomes.
Finally, separate analyses with each MetS component
yielded only nonsignificant results for walking speed, grip
strength, SPPB, and disability score. In the overall sample,
all components with the exception of abdominal obesity
(P = .86) were associated with worse SRH (P = .02 for
TG, P = .02 for HDL, P = .01 for BP, P < .001 for glu-
cose); in analyses stratified according to diabetes mellitus
status, the only association that remained statistically
significant was between low HDL-C and worse SRH in
participants without diabetes mellitus (P = .04).
DISCUSSION
This study offers three main findings. First, MetS was
highly prevalent in this sample of adults aged 70 and older
at high risk of disability, being identified in one out of two
participants. Second, the prevalence of MetS and its com-
ponents differed according to participants’ age, education,
BMI, and diabetes mellitus status. Third, after adjustment
for known and potential confounders, MetS was associated
with stronger grip strength (in the overall sample and in
participants without diabetes mellitus) and worse SRH (in
the overall sample only) but not with walking speed, SPPB
score, or self-reported disability.
Understanding the current demographic distribution of
MetS and its components in older adults at risk of disabilityT
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may help to customize clinical and public health initiatives
aimed at reducing disability in older adults. In contrast to
previous findings showing a higher prevalence of MetS and
abdominal obesity in women than in men8,38–40 the current
study found only a higher rate of glucose intolerance in
men. The cardiometabolic profiles of men and women were
otherwise comparable. Higher educational achievement was
correlated with lower rates of MetS and all its components
except high blood glucose. An age-related decrease in the
prevalence of MetS after age 70 was also found, from
approximately 60% of participants younger than 75 to
approximately 30% in the oldest group (≥85), with a
decreasing prevalence of all MetS components with advanc-
ing age except for hypertension. The cross-sectional nature
of the data precluded further investigation of whether the
observed association between older age and “better” meta-
bolic profiles is due to true age differences (improvement in
levels of metabolic markers with age), to differences
between older and younger cohorts (worse metabolic pro-
files in younger cohorts), or to a healthy-survivor effect
(“resilient” individuals with better metabolic profiles surviv-
ing longer than those with worse metabolic profiles).
Although these findings on educational and age differences
in the rates of MetS and its components are generally consis-
tent with nationally representative estimates from the
National Health and Nutrition Examination Survey using
the new harmonized MetS definition8 and with other studies
that have investigated sociodemographic determinants of
metabolic dysfunction,41,42 more research, particularly
using longitudinal data, is needed to better understand the
mechanisms underlying such differences.
Previous investigations of the relationship between
MetS and various objective indicators of physical capacity
have focused on the general population of older adults,
rather than on those at high risk of disability, with mixed
results; although several studies have found weaker grip
strength, slower walking speed, and poorer balance in par-
ticipants with MetS than in those without,12–14 others have
found no such associations.35 The results from the current
sample of high-risk older adults show that the association
with MetS varies across the three measures of physical
capacity. First, walking speed was comparable in partici-
pants with and without MetS in the adjusted model and
separately in participants with and without diabetes mell-
itus, indicating that the difference in walking speed
observed in the unadjusted model was due to other demo-
graphic and health differences between the MetS sub-
groups. Furthermore, there were no associations between
walking speed and individual MetS components or severity
of MetS. The relationship between metabolic profiles and
walking speed has been evaluated in women43 or men
only12 or in general-risk populations.35 Because these stud-
ies have reported conflicting results, further research is
needed to substantiate the current study’s findings.
Second, in contradiction to the hypothesis and to
results from several previous studies,14,44 grip strength was
stronger in the overall MetS subgroup and in participants
with MetS and without diabetes mellitus. Although this
seemingly paradoxical finding cannot be fully explained, it
is possible that the higher BMI in MetS participants than
in those without was a reflection of not only higher fat
mass (as indicated by the higher rates of abdominal obesity
in the MetS group), but also of higher muscle mass than in
the non-MetS group, resulting in better grip strength.
Although body composition measures were not available
for further analysis, a prior study showing that, for all
BMI categories, older persons with MetS had higher mus-
cle mass than those with a similar BMI but no MetS indi-
rectly supports this explanation.39 Additional studies are
warranted to confirm the finding and to investigate poten-
tial mechanisms linking MetS to upper extremity muscle
mass and grip strength.
Third, lower extremity function as measured accord-
ing to SPPB score was not associated with MetS in any of
the models or subgroups. Although these results may
reflect a true lack of association between lower extremity
function and MetS, they may also represent a statistical
artifact. Based on the eligibility criteria, LIFE participants
were required to be able to walk unassisted at a speed
compatible with independent living (excluding those at the
very low end of SPPB scores) and to be at high risk of
mobility disability as indicated by an SPPB score of 9 or
less. By reducing variability across subgroups, the trun-
cated range of SPPB scores in the resulting sample may
have limited the ability to detect differences.
After adjustment for demographic and health charac-
teristics, no differences were found in disability scores,
which combined self-reports of mobility abilities and ADLs
and IADLs, according to MetS status in the full sample or
in the subgroups with and without diabetes mellitus. The
existing literature is also conflicting regarding the relation-
ship between MetS and self-reported functional status in
the general older population; although some studies have
shown a greater burden of mobility and IADL disability in
the setting of MetS,34,45 others have found no associa-
tion46 and even a protective effect of MetS on ADL dis-
ability.44 Because of differences in the initial risk profile
(high disability risk vs general population) and disability
assessment between the current study sample and samples
from prior studies, the results of the current study cannot
lend support to either side. Additional research is needed
to further evaluate the cross-sectional and longitudinal
associations between potentially treatable metabolic abnor-
malities and various domains of disability in older adults.
In the overall sample, participants with MetS had
marginally worse self-assessments of health than their non-
MetS counterparts. Self-rated health also showed a gradi-
ent according to MetS severity and was independently
associated with several MetS components in the overall
sample and with low HDL-C in participants without dia-
betes mellitus, but the clinical significance of these differ-
ences (the largest difference between MetS and non-MetS
participants was 0.2 in the overall sample) is uncertain
because the minimum or meaningful clinically important
difference47 in SRH has not been clearly established.
The value of MetS, in addition to that of its individual
components, as an independent predictor of other impor-
tant health outcomes has been called into question.10 The
current study found nonsignificant associations between
the MetS composite and walking speed, lower extremity
function, and self-reported disability, and between individ-
ual MetS components and MetS severity and most out-
comes (except SRH). Although these results may reflect a
true lack of association, two alternate explanations need
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to be considered. First, it is possible that the LIFE recruit-
ment strategy, which excluded individuals at the high and
low end of functional status, may have restricted the range
of variation in these outcomes and thus reduced the power
to detect statistically significant differences. Second, the
nonsignificant effect of MetS on these and other outcomes
may be due to selective survival; specifically, members of
the cohort who were “susceptible” to the negative influ-
ence of MetS may have already died, resulting in a study
population comprised of “MetS resistant” individuals. The
cross-sectional nature of the data prevented further investi-
gation into the possibility of selection or survival bias.
Longitudinal analyses are warranted to determine whether
MetS is associated with reductions in physical capacity
and greater disability in later life. A third limitation of this
study is the use of a summary disability score; although
the disability assessment instrument has been shown to be
valid, reliable, and sensitive to change,29 it may have
obscured more subtle associations between MetS and
selected functional domains (mobility, ADLs, IADLs) or
tasks. Fourth, because the participants were enrolled in the
LIFE Study, a randomized controlled trial aimed at pre-
venting mobility decline in older, sedentary men and
women with an SPPB score of 9 or less, the results may
not be generalizable to individuals who do not meet these
criteria. Nonetheless, given that many older adults in the
United States are sedentary and have functional limita-
tions, the results are likely to be representative of a sub-
stantial proportion of community-living older men and
women.
Although approximately half of older adults at risk
of mobility disability participating in the LIFE Study have
metabolic profiles consistent with MetS, an association
between MetS and walking speed, lower extremity func-
tion, and self-reported disability remains to be estab-
lished. Longitudinal studies are needed to investigate
whether the metabolic dysregulation characterized by
MetS accelerates declines in functional status over time.
This knowledge may in turn inform clinical and public
health interventions aimed at preventing or delaying
disability in older adults.
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